Abstract
The genetic, cellular, and molecular changes associated with Alzheimer disease provide evidence of immune and inflammatory processes involvement in its pathogenesis. These are supported by epidemiological studies, which show some benefit of long-term use of NSAID. The hypothesis that AD is in fact an immunologically mediated and even inflammatory pathological process may be in fact scientifically intriguing. There are several obstacles that suggest the need for more complex view, in the process of targeting inflammation and immunity in AD. In our previous studies we proposed a reliable methodology to assess innate immunity in Alzheimer patients and controls. The methodology is based on the phenomenon of human leukocytes being resistant to viral infection. The unspecific character of the resistance, dependent on interferons and tumor necrosis factor, and occurrence in cells ex vivo indicate that an in vivo mechanism of innate immunity may be involved. The above mentioned resistance could be estimated in a test based on peripheral blood leukocytes infection by vesicular stomachs virus.
Keywords: Alzheimer disease, human peripheral blood leukocytes, innate immunity, therapy.
Current Pharmaceutical Design
Title:The Innate Immunity in Alzheimer Disease- Relevance to Pathogenesis and Therapy
Volume: 21 Issue: 25
Author(s): Zofia Blach-Olszewska, Ewa Zaczynska, Kasia Gustaw-Rothenberg, Marco Avila-Rodrigues, George E. Barreto, Jerzy Leszek and Gjumrakch Aliev
Affiliation:
Keywords: Alzheimer disease, human peripheral blood leukocytes, innate immunity, therapy.
Abstract: The genetic, cellular, and molecular changes associated with Alzheimer disease provide evidence of immune and inflammatory processes involvement in its pathogenesis. These are supported by epidemiological studies, which show some benefit of long-term use of NSAID. The hypothesis that AD is in fact an immunologically mediated and even inflammatory pathological process may be in fact scientifically intriguing. There are several obstacles that suggest the need for more complex view, in the process of targeting inflammation and immunity in AD. In our previous studies we proposed a reliable methodology to assess innate immunity in Alzheimer patients and controls. The methodology is based on the phenomenon of human leukocytes being resistant to viral infection. The unspecific character of the resistance, dependent on interferons and tumor necrosis factor, and occurrence in cells ex vivo indicate that an in vivo mechanism of innate immunity may be involved. The above mentioned resistance could be estimated in a test based on peripheral blood leukocytes infection by vesicular stomachs virus.
Export Options
About this article
Cite this article as:
Blach-Olszewska Zofia, Zaczynska Ewa, Gustaw-Rothenberg Kasia, Avila-Rodrigues Marco, Barreto E. George, Leszek Jerzy and Aliev Gjumrakch, The Innate Immunity in Alzheimer Disease- Relevance to Pathogenesis and Therapy, Current Pharmaceutical Design 2015; 21 (25) . https://dx.doi.org/10.2174/1381612821666150710144829
DOI https://dx.doi.org/10.2174/1381612821666150710144829 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bioinformatics Approach to BDNF and BDNF-Related Disorders
Current Neuropharmacology Therapeutic Agents in Alzheimer's Disease Through a Multi-targetdirected Ligands Strategy: Recent Progress Based on Tacrine Core
Current Topics in Medicinal Chemistry Meet Our Associate Editor
Central Nervous System Agents in Medicinal Chemistry Thrombomodulin – A New Target for Treating Stroke at the Crossroad of Coagulation and Inflammation
Current Medicinal Chemistry Lipoic Acid: A Novel Therapeutic Approach for Multiple Sclerosis and Other Chronic Inflammatory Diseases of the CNS
Endocrine, Metabolic & Immune Disorders - Drug Targets Nitric Oxide and Schizophrenia: Present Knowledge and Emerging Concepts of Therapy
CNS & Neurological Disorders - Drug Targets Acknowledgement List of the Reviewers
Current Alzheimer Research A Possible New Diagnostic Biomarker in Early Diagnosis of Alzheimers Disease
Current Alzheimer Research A Therapeutic Target of Cerebral Hemorrhagic Stroke: Matrix Metalloproteinase- 9
Current Drug Targets Pharmacotherapy of Sickle Cell Disease in Children
Current Pharmaceutical Design Therapeutic Approaches of Leptin in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Radiolabeled Peptides for Alzheimer’s Diagnostic Imaging: Mini Review
Current Radiopharmaceuticals Issues of Quantitative Metabolic Brain Imaging with Small Animal PET in Mice
Current Medical Imaging The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Editorial [Hot Topic: Brain Resilience and Plasticity in the Face of Alzheimer Pathology (Guest Editor: Ira Driscoll & Juan Troncoso)]
Current Alzheimer Research Abeta Immunotherapy and Other Means to Remove Amyloid
Current Drug Targets - CNS & Neurological Disorders Medicinal and Beneficial Health Applications of Tinospora cordifolia (Guduchi): A Miraculous Herb Countering Various Diseases/Disorders and its Immunomodulatory Effects
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Oxidative Stress in Post-Acute Ischemic Stroke Patients after Intensive Neurorehabilitation
Current Neurovascular Research Antipsychotic-Induced Electrocardiographic Changes: A Comparative Study Between Olanzapine and Risperidone
Current Psychopharmacology Pharmacogenomics: A Tool to Prevent and Cure Coronary Heart Disease
Current Pharmaceutical Design